Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Endocrinology
Tissue-selective effects of tibolone on the breast examined
December 23rd, 2004
Tissue-selective effects of tibolone, a synthetic hormone, on the breast were assessed by researchers with NV Organon, which manufactures tibolone and markets it under the brand name Livial. "Hormone treatment with an estrogen plus a progestagen (EPT) increases the risk of breast cancer. Both hormone activities are also induced by tibolone. In order to assess the breast safety of tibolone, it was evaluated in several pre-clinical models," said H.J. Kloosterboer and colleagues. They reported, "The effects were inconclusive in breast cancer cell lines but, in various in vivo models, it did not stimulate the breast. In the...
Source: Women's Health Weekly (2004-12-23)
|
